Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Charcot-Marie-Tooth Experts Launch Organization to Fund Treatments and Cures

By CMT Research Foundation | October 23, 2018

Two experts in Charcot-Marie-Tooth (CMT), who also have the condition, recently launched the CMT Research Foundation (CMTRF) as the only 501(c)(3) not-for-profit organization focused solely on delivering treatments and cures for CMT.

Patrick Livney, a former chairman of CMTA, and Susan Ruediger, a former CMTA development director, have more than 20 years of collective experience working with CMT researchers to deliver treatments. By developing partnerships with researchers, pharmaceutical and biotechnology professionals, as well as a national network of CMT patients, they have been instrumental in achieving recent, successful milestones in CMT research.

CMT is a progressive genetic nerve disease and can lead to severe disability or even death. CMT has more than 90 known genetic causes and can be passed down in multiple generations. Onset can be at birth or later in life and is characterized by loss of muscles and sensation in the feet, hands, legs, and arms. Nearly three million people of every age, race, and ethnicity are living with CMT. Currently there is no cure for CMT; and there are not any effective treatments. 

“The CMT Research Foundation will play a unique role in the CMT community by limiting overhead and focusing on funding research that will help speed cures not only for various levels of CMT, but also other neurological degenerative diseases including ALS and Alzheimer’s,” Livney said.

The CMTRF will support promising and effective research aimed at drug delivery by developing strategic alliances with academic and industry stakeholders. With the help of an advisory board comprised of academic, medical, and biotech experts, the CMTRF will fund translational research for all types of CMT. 

(Source: CMT Research Foundation)


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50